Literature DB >> 7744500

Activation of tumor necrosis factor--alpha system in HIV-1 infection: association with markers of immune activation.

P Aukrust1, N B Liabakk, F Müller, T Espevik, S S Frøland.   

Abstract

The relationships between serum levels of soluble tumor necrosis factor receptors (sTNFRs) and other prognostic and immunological parameters in different immunological subgroups of 64 HIV-1 infected patients were studied. In the patient group as a whole, the raised serum levels of sTNFRs were significantly inversely correlated to the numbers of CD4+ and CD8+ lymphocytes and significantly positively correlated with serum levels of neopterin, HIV-1 p24 antigen and the soluble CD8/CD8+ lymphocyte ratio. However, when the patients were classified into three separate immunological subgroups according to the numbers of CD4+ lymphocytes, only serum levels of neopterin were significantly correlated to levels of sTNFRs in all the defined immunological subgroups. These results indicate that HIV-1 infection is associated with a persistent and chronic immune activation in the TNF system manifested by raised serum levels of sTNFRs, which may reflect sustained activation of the immune system particularly in monocytes/macrophages. Further, these results confirm that, when comparing immunological and virological parameters in HIV-1 infection, different results may be obtained in different immunological subgroups of patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744500     DOI: 10.1007/BF01710050

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  39 in total

1.  Prognostic value of an elevated CD8 lymphocyte count in HIV infection. Results of a prospective study of 152 asymptomatic HIV-positive individuals.

Authors:  S Chevret; H Roquin; P Ganne; J J Lefrère
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

2.  CD8 T lymphocyte subset markers and HIV infection.

Authors:  A G Bird; K C Watret
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

3.  Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?

Authors:  T Matsuyama; N Kobayashi; N Yamamoto
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

4.  The release of soluble p55 TNF receptor from U937 cells studied by a new p55 immunoassay.

Authors:  N B Liabakk; A Sundan; E Lien; A Laegreid; M P Bombara; G Ranges; T Espevik
Journal:  J Immunol Methods       Date:  1993-08-09       Impact factor: 2.303

5.  Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes.

Authors:  A Kalinkovich; G Livshits; H Engelmann; N Harpaz; R Burstein; M Kaminsky; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

6.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

Authors:  D Aderka; H Englemann; V Hornik; Y Skornick; Y Levo; D Wallach; G Kushtai
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

7.  Two types of TNF receptors are expressed on human normal and malignant B lymphocytes.

Authors:  B Heilig; M Mapara; M Brockhaus; K Krauth; B Dörken
Journal:  Clin Immunol Immunopathol       Date:  1991-11

8.  High concentrations of soluble tumor necrosis factor receptors in ascites.

Authors:  T Andus; V Gross; A Holstege; M Ott; M Weber; M David; H Gallati; W Gerok; J Schölmerich
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

9.  Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group.

Authors:  E Girardin; P Roux-Lombard; G E Grau; P Suter; H Gallati; J M Dayer
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

10.  Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection.

Authors:  M H Godfried; T van der Poll; J Jansen; J A Romijin; J K Schattenkerk; E Endert; S J van Deventer; H P Sauerwein
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

View more
  7 in total

1.  Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients.

Authors:  F Ajello; R La Licata; M Lodato; F Vitale; F Bonura; R Valenti; M Bruno; N Romano
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

2.  Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection.

Authors:  M Weiss; M Martignoni; T Petropoulou; B Sölder; B H Belohradsky
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

Review 3.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.

Authors:  A De Milito; S Aleman; R Marenzi; A Sonnerborg; D Fuchs; M Zazzi; F Chiodi; Fuchs D
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

5.  High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients.

Authors:  D Hober; S Benyoucef; A S Delannoy; D de Groote; F Ajana; Y Mouton; P Wattré
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

Review 6.  The lymph node in HIV pathogenesis.

Authors:  Michael M Lederman; Leonid Margolis
Journal:  Semin Immunol       Date:  2008-07-14       Impact factor: 11.130

7.  Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Authors:  Jyoti S Mathad; Nikhil Gupte; Ashwin Balagopal; David Asmuth; James Hakim; Breno Santos; Cynthia Riviere; Mina Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Noluthando Mwelase; Jyoti Pawar; Sima Berendes; Nagalingeswaran Kumarasamy; Bruno B Andrade; Thomas B Campbell; Judith S Currier; Susan E Cohn; Amita Gupta
Journal:  J Acquir Immune Defic Syndr       Date:  2016-10-01       Impact factor: 3.731

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.